Geode Capital Management LLC grew its position in Mesa Laboratories, Inc. (NASDAQ:MLAB - Free Report) by 4.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 124,761 shares of the medical instruments supplier's stock after purchasing an additional 5,771 shares during the period. Geode Capital Management LLC owned approximately 2.30% of Mesa Laboratories worth $16,205,000 as of its most recent SEC filing.
Several other large investors also recently made changes to their positions in MLAB. Barclays PLC boosted its position in Mesa Laboratories by 357.4% during the 3rd quarter. Barclays PLC now owns 8,837 shares of the medical instruments supplier's stock worth $1,148,000 after acquiring an additional 6,905 shares during the period. XTX Topco Ltd bought a new stake in shares of Mesa Laboratories during the third quarter valued at about $388,000. State Street Corp lifted its holdings in Mesa Laboratories by 9.2% in the third quarter. State Street Corp now owns 214,148 shares of the medical instruments supplier's stock worth $27,809,000 after purchasing an additional 18,128 shares during the period. Quadrature Capital Ltd bought a new position in Mesa Laboratories in the 3rd quarter valued at about $221,000. Finally, PDT Partners LLC acquired a new position in Mesa Laboratories during the 3rd quarter valued at about $295,000. Institutional investors and hedge funds own 90.60% of the company's stock.
Analyst Ratings Changes
A number of brokerages have recently weighed in on MLAB. StockNews.com lowered shares of Mesa Laboratories from a "buy" rating to a "hold" rating in a research note on Wednesday, November 13th. Evercore ISI upped their target price on Mesa Laboratories from $120.00 to $160.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 1st.
View Our Latest Research Report on Mesa Laboratories
Insider Buying and Selling
In other news, CEO Gary M. Owens sold 2,518 shares of the business's stock in a transaction on Monday, October 28th. The stock was sold at an average price of $113.62, for a total transaction of $286,095.16. Following the sale, the chief executive officer now directly owns 45,888 shares of the company's stock, valued at $5,213,794.56. The trade was a 5.20 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.40% of the stock is currently owned by insiders.
Mesa Laboratories Price Performance
Mesa Laboratories stock traded down $1.02 during midday trading on Monday, hitting $132.04. The company's stock had a trading volume of 22,211 shares, compared to its average volume of 41,441. Mesa Laboratories, Inc. has a 12 month low of $83.68 and a 12 month high of $141.17. The company has a quick ratio of 0.51, a current ratio of 0.70 and a debt-to-equity ratio of 0.65. The stock's 50-day moving average price is $120.53 and its 200-day moving average price is $117.72. The company has a market capitalization of $717.11 million, a PE ratio of -2.90 and a beta of 0.86.
Mesa Laboratories Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Monday, December 16th. Investors of record on Friday, November 29th were paid a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.48%. The ex-dividend date of this dividend was Friday, November 29th. Mesa Laboratories's dividend payout ratio is presently -1.40%.
Mesa Laboratories Company Profile
(
Free Report)
Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.
Further Reading
Before you consider Mesa Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesa Laboratories wasn't on the list.
While Mesa Laboratories currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
